Table 3.
Univariate and multivariate analyses of the OS and breast cancer-specific survival BCSS of the study population after PSM.
| Univariate analysis | Multivariate analysis | |||||||
|---|---|---|---|---|---|---|---|---|
| Variable | BCSS | OS | BCSS | OS | ||||
| HR (95% CI) | p | HR (95% CI) | p | HR (95% CI) | p | HR (95% CI) | p | |
| Age | ||||||||
| 18–39 | 1 | 1 | 1 | 1 | ||||
| ≥40 | 1.120 (0.929–1.340) | 0.242 | 1.230 (1.030–1.460) | <0.05 | 1.205 (0.998–1.455) | 0.052 | 1.324 (1.106–1.585) | <0.05 |
| Race | ||||||||
| White | 1 | 1 | 1 | 1 | ||||
| Black | 1.900 (1.540–2.330) | <0.05 | 1.840 (1.510–2.240) | <0.05 | 1.467 (1.184–1.819) | <0.05 | 1.411 (1.149–1.733) | <0.05 |
| Other/unknown | 1.270 (0.943–1.720) | 0.116 | 1.230 (0.922–1.640) | 0.159 | 1.159 (0.844–1.593) | 0.362 | 1.100 (0.810–1.492) | 0.542 |
| T stage | ||||||||
| T0/T1 | 1 | 1 | 1 | 1 | ||||
| T2/T3 | 1.080 (0.785–1.490) | 0.637 | 0.996 (0.741–1.340) | 0.977 | 1.193 (0.852–1.670) | 0.305 | 1.133 (0.828–1.551) | 0.435 |
| T4 | 1.510 (1.080–2.130) | <0.05 | 1.410 (1.030–1.940) | <0.05 | 1.568 (1.084–2.2690 | <0.05 | 1.507 (1.068–2.126) | <0.05 |
| Tx | 1.280 (0.859–1.910) | 0.225 | 1.190 (0.816–1.720) | 0.372 | 1.144 (0.755–1.732) | 0.526 | 1.016 (0.688–1.501) | 0.936 |
| N stage | ||||||||
| N0 | 1 | 1 | 1 | 1 | ||||
| N1/N2 | 0.839 (0.656–1.070) | 0.161 | 0.806 (0.638–1.020) | 0.071 | 0.800 (0.616–1.040) | <0.05 | 0.778 (0.606–0.999) | <0.05 |
| N3 | 0.981 (0.720–1.340) | 0.904 | 1.010 (0.755–1.350) | 0.947 | 0.887 (0.635–1.241) | 0.484 | 0.923 (0.673–1.267) | 0.622 |
| Nx | 0.945 (0.596–1.500) | 0.812 | 1.180 (0.7921–1.770) | 0.41 | 0.762 (0.470–1.236) | 0.271 | 1.005 (0.658–1.534) | 0.983 |
| Radiation | ||||||||
| No | 1 | 1 | 1 | 1 | ||||
| Yes | 0.880 (0.731–1.060) | 0.177 | 0.814 (0.682–0.973) | <0.05 | 1.154 (0.939–1.418) | 0.175 | 1.051 (0.862–1.280) | 0.624 |
| Chemotherapy | ||||||||
| No | 1 | 1 | 1 | 1 | ||||
| Yes | 0.684 (0.553–0.845) | 0.667 (0.546–0.815) | <0.05 | 0.807 (0.634–1.028) | 0.083 | 0.748 (0.595–0.939) | <0.05 | |
| Surgery | ||||||||
| No | 1 | 1 | 1 | 1 | ||||
| Yes | 0.525 (0.430–0.642) | <0.05 | 0.550 (0.455–0.665) | <0.05 | 0.596 (0.474–0.748) | <0.05 | 0.632 (0.510–0.784) | <0.05 |
| Subtype | ||||||||
| Luminal A | 1 | 1 | 1 | 1 | ||||
| Luminal B | 0.508 (0.396–0.653) | <0.05 | 0.530 (0.419–0.671) | <0.05 | 0.503 (0.387–0.654) | <0.05 | 0.532 (0.415–0.682) | <0.05 |
| HER2-enriched | 0.541 (0.379–0.772) | <0.05 | 0.527 (0.373–0.744) | <0.05 | 0.560 (0.386–0.814) | <0.05 | 0.556 (0.387–0.798) | <0.05 |
| Triple-negative | 3.281 (2.517–4.276) | <0.05 | 3.407 (2.655–4.372) | <0.05 | 3.334 (2.451–4.534) | <0.05 | 3.375 (2.527–4.507) | <0.05 |
| Unknown | 1.402 (0.964–2.040) | 0.077 | 1.412 (0.987–2.021) | 0.059 | 1.290 (0.876–1.901) | 0.198 | 1.317 (0.910–1.907) | 0.145 |
| Metastatic sites | ||||||||
| Bone | 1 | 1 | 1 | 1 | ||||
| Brain | 10.100 (4.690–21.700) | <0.05 | 10.300 (5.010–21.100) | <0.05 | 10.537 (4.777–23.238) | <0.05 | 10.526 (5.024–22.052) | <0.05 |
| Liver | 0.936 (0.666–1.320) | 0.702 | 0.996 (0.725–1.370) | 0.982 | 1.083 (0.754–1.557) | 0.666 | 1.120 (0.799–1.571) | 0.511 |
| Lung | 0.890 (0.539–1.470) | 0.647 | 1.000 (0.637–1.580) | 0.992 | 0.722 (0.421–1.238) | 0.236 | 0.826 (0.505–1.351) | 0.446 |
| Distant lymph nodes | 0.581 (0.369–0.917) | <0.05 | 0.631 (0.414–0.960) | <0.05 | 0.650 (0.405–1.045) | 0.075 | 0.661 (0.427–1.025) | 0.065 |
| Multiple sites | 1.700 (1.380–2.080) | <0.05 | 1.660 (1.360–2.020) | <0.05 | 1.459 (0.685–1.837) | 0.001 | 1.429 (1.146–1.783) | <0.05 |
OS, overall survival; BCSS, cancer-specific survival; HRs, hazard ratios; CI, confidence interval.